{
    "title": "Prostate cancer drug rejected for use on the NHS",
    "url": "https://www.dailymail.co.uk/wires/pa/article-10369725/Prostate-cancer-drug-rejected-use-NHS.html",
    "date": "2022-01-05",
    "keywords": [
        "cancer",
        "olaparib",
        "prostate",
        "drug",
        "treatment",
        "nhs",
        "use",
        "nice",
        "evidence",
        "price",
        "england",
        "cabazitaxel",
        "trial",
        "professor",
        "guidance",
        "institute",
        "care",
        "body",
        "retreatment",
        "abiraterone",
        "profound",
        "icr",
        "decision",
        "executive",
        "way",
        "draft",
        "health",
        "excellence",
        "lynparza",
        "list",
        "pack",
        "supply",
        "cost",
        "course",
        "astrazeneca",
        "arrangement",
        "discount",
        "brca1",
        "brca2",
        "hormone",
        "therapy",
        "time",
        "disease",
        "enzalutamide",
        "comparison",
        "watchdog",
        "research",
        "london",
        "inhibitor",
        "brcamutant",
        "news",
        "average",
        "johann",
        "medicine",
        "leader",
        "precision",
        "life",
        "chemotherapy",
        "scotland",
        "year",
        "disappointing",
        "option",
        "example",
        "postcode",
        "prescribing",
        "uk",
        "helin",
        "urge",
        "manufacturer",
        "table",
        "agreement",
        "access",
        "flexibility",
        "indication",
        "return",
        "leng",
        "companys",
        "model",
        "benefit",
        "company",
        "committee"
    ],
    "category": [
        "wires",
        "pa"
    ]
}